Combination anti-CD137 and anti-CD40 antibody therapy in murine myc-driven hematological cancers

Jennifer A. Westwood, Geoffrey M. Matthews, Jake Shortt, David Faulkner, Hollie J. Pegram, Connie P.M. Duong, Marta Chesi, P. Leif Bergsagel, Leslie L. Sharp, Richard D. Huhn, Phillip K. Darcy, Ricky W. Johnstone, Michael H. Kershaw

Research output: Contribution to journalArticlepeer-review

11 Scopus citations


In order to stimulate antigen presentation and T cell activity against cancer, we treated three different tumor models in mice with the monoclonal antibodies anti-CD40 plus anti-CD137 (BiMab). In a subcutaneous transplantable MC38 colon cancer model, there was significant enhancement in the survival of mice following BiMab treatment. Anti-CD40 has shown considerable success against lymphoma in previous studies by other investigators, and we also showed in this study that, in a model of Eμ-Myc lymphoma, there was a statistically significant enhancement of survival of mice following BiMab treatment. Following the success of the BiMab treatment in the previous two models, we wished to determine if it would be successful in a mouse model of multiple myeloma. Firstly, we tested a transplantable model of disease in which multiple myeloma cells derived from Vk*MYC mice were injected intravenously. A minor proportion of anti-CD137 and BiMab treated mice experienced prolongation of life beyond 250 days. Then we tested the therapy in a spontaneously occurring multiple myeloma model, in Vk*MYC transgenic mice. The majority of mice treated survived longer than control mice, although statistical significance was not demonstrated.

Original languageEnglish (US)
Pages (from-to)948-954
Number of pages7
JournalLeukemia Research
Issue number8
StatePublished - Aug 2014


  • Anti-CD137
  • Anti-CD40
  • Eμ-Myc
  • Lymphoma
  • Multiple myeloma
  • myc

ASJC Scopus subject areas

  • Hematology
  • Oncology
  • Cancer Research


Dive into the research topics of 'Combination anti-CD137 and anti-CD40 antibody therapy in murine myc-driven hematological cancers'. Together they form a unique fingerprint.

Cite this